Who Paid My Doc
Rachel Dew
Psychiatry Durham, NC Medical Doctor
NPI 1619131372 CMS profile 300396
Dumc, Box 3875, Durham, NC 27710
General payments
$62
Research payments
$8,077
Ownership & investment interest
$0
Research they led as principal investigator
$520,276
Through program year 2024, Rachel Dew of Durham, NC is reported in the CMS Open Payments database as having received $62 across 1 general payment and $8,077 in research payments paid to them. Separately, studies naming them as principal investigator received $520,276 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $62 | 1 | |
| 2022 | Research | $7,864 | 4 | |
| 2019 | Research | $213 | 3 |
Beside peers
- Rachel Dew
- Psychiatry median
- Middle half of Psychiatry
- National median
In program year 2025, general payments to Rachel Dew were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.
Show as a table
| Year | Rachel Dew | Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $184 | $59–$605 | $163 |
| 2020 | $0 | $119 | $36–$372 | $114 |
| 2021 | $0 | $143 | $43–$576 | $132 |
| 2022 | $0 | $153 | $50–$590 | $149 |
| 2023 | $0 | $170 | $56–$651 | $160 |
| 2024 | $62 | $179 | $57–$673 | $164 |
| 2025 | $0 | $180 | $58–$685 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
201
Drug cost
$14,728
Branded share of claims
37.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Methylphenidate Er Methylphenidate Hcl | Brand | 11 | $4,582 | |
| Vyvanse Lisdexamfetamine Dimesylate | Brand | 11 | $4,194 | |
| Methylphenidate Er (La) Methylphenidate Hcl | Brand | 19 | $1,425 | |
| Methylphenidate Hcl | Generic | 24 | $1,238 | |
| Atomoxetine Hcl | Generic | 20 | $1,046 | |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 23 | $748 | |
| Quetiapine Fumarate | Generic | 13 | $525 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 11 | $340 | |
| Duloxetine Hcl | Generic | 11 | $299 | |
| Alprazolam | Generic | 42 | $258 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.
Records
8 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Psychiatry in North Carolina
Related records
Psychiatry in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.